Supernus Pharmaceuticals

Yahoo Finance • yesterday

3 Unprofitable Stocks We Think Twice About

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. A lack of profits can lead to trouble, but... Full story

Yahoo Finance • last month

3 Reasons SUPN is Risky and 1 Stock to Buy Instead

Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, marking a 17.1% gain. This was partly thanks to its solid quarterly results, and th... Full story

Yahoo Finance • 2 months ago

Supernus Pharmaceuticals to Participate in March Investor Conferences

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story

Yahoo Finance • 4 months ago

Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

Key Points Aristotle Capital Boston sold 503,122 shares of Supernus Pharmaceuticals in the third quarter. The move contributed to a net position change of about $10.9 million from the previous quarter. As of September 30, Aristotle Capita... Full story

Yahoo Finance • 4 months ago

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story

Yahoo Finance • 5 months ago

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story

Yahoo Finance • 5 months ago

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valu... Full story

Yahoo Finance • 5 months ago

Supernus Pharmaceuticals (SUPN) is Benefiting from Its Strength in Financial Position

Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Small-Cap Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fun... Full story

Yahoo Finance • 5 months ago

Supernus Announces Third Quarter 2025 Financial Results

Combined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024. This strong growth was driven by an increase in net sales of Qelbree® and GOCOVRI®,... Full story

Yahoo Finance • 6 months ago

Supernus a new buy at BofA on 'underappreciated' CNS assets

[Wall Street sign with American flag in the background, symbolizing the financial heart of New York.] BofA Securities has initiated coverage of Supernus Pharmaceuticals (SUPN [https://seekingalpha.com/symbol/SUPN]) at buy saying that the... Full story

Yahoo Finance • 6 months ago

Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Piper Sandler upgraded Skyworks (SWKS)... Full story

Yahoo Finance • 6 months ago

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t... Full story

Yahoo Finance • 6 months ago

How The Pieces Add Up: JSMD Headed For $90

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 7 months ago

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11The approval of thi... Full story

Yahoo Finance • 7 months ago

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Emerges as a Top Affordable Growth Stock

Investors looking for growth chances at fair prices often consider methods that find companies with good expansion possibilities without high costs. The Affordable Growth method centers on stocks showing strong growth paths, good profitabi... Full story

Yahoo Finance • 8 months ago

Supernus Pharmaceuticals to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story

Yahoo Finance • 8 months ago

Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN)

Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Small-Cap Value Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fu... Full story

Yahoo Finance • 8 months ago

Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel

Investing.com - Stifel raised its price target on Supernus Pharmaceuticals (NASDAQ:SUPN) to $43.00 from $38.00 on Wednesday, while maintaining a Hold rating on the stock. According to InvestingPro data, the stock is currently trading near... Full story

Yahoo Finance • 8 months ago

Supernus raises 2025 revenue guidance to $670M-$700M following Sage acquisition and strong core product growth

Earnings Call Insights: Supernus Pharmaceuticals (SUPN) Q2 2025 MANAGEMENT VIEW * CEO Jack A. Khattar stated that "Supernus continues to execute well against its growth plan and had a strong and very active second quarter." He highligh... Full story

Yahoo Finance • 8 months ago

Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses

Supernus Pharmaceuticals reported its Q2 2025 earnings, revealing a mixed financial performance. The company achieved a revenue of $165 million, surpassing the forecast of $154.3 million by 7.26%. However, its earnings per share (EPS) fell... Full story